Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus XELOX for resectable esophagogastric junction adenocarcinoma
NCT06482788Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in esophagogastric junction adenocarcinoma (GEJA), sponsored by Ruijin Hospital. Primary endpoint: Pathological Complete Response Rate. Started May 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
esophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT06482788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482788.